Table 1 Baseline patient characteristics
Characteristic | N = 18 |
|---|---|
On-study age—years |  |
Median | 57 |
Range | 25—81 |
Sex-no. (%) | Â |
Female | 10 (56) |
Male | 8 (44) |
Ethnicity-no. (%) | Â |
Non-hispanic white | 7 (39) |
Non-hispanic African-American | 6 (33) |
Other | 5 (28) |
Primary site (%)* | Â |
Left colon/rectum | 11 (61) |
Right colon | 6 (33) |
Histologic grade | Â |
Well differentiated | 0 (0) |
Moderately differentiated | 14 (78) |
Poorly differentiated | 2 (11) |
Unknown | 2 (11) |
Time from metastatic diagnosis-months | Â |
Median | 32 |
Range | 4—172 |
Metastatic site (%) | Â |
Liver only | 4 |
Lymph nodes only | 1 |
Bladder only | 1 |
Multiple sites | 12 |
Exposure to prior therapies (%) | Â |
Fluoropyrimidine | 18 (94) |
Oxaliplatin | 17 (94) |
Irinotecan | 17 (94) |
Anti-VEGF | 17 (94) |
Anti-EGFR | 8 (44) |
KRAS mutation status | Â |
Wild-type | 7 |
Mutant | 9 |
Unknown | 2 |
Microsatellite Instability/Mismatch Repair Status | Â |
MSI-H/dMMR | 1 |
MSS/pMMR | 12 |
Unknown | 5 |